Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process

Table 6 2000 Cohort/Patients on OA/RA medications who also had CVD, CVA or renal morbidity, by age and sex

	OA/RA drugs plus cardiovascular disease		*Male* vs. *Female*	OA/RA drugs plus cerebrovascular disease		*Male* vs. *Female*	OA/RA drugs plus renal disease		*Male* vs. *Female*
Age Group	Male	Female	%	Male	Female	%	Male	Female	%
65-69	356	203	64 : 36	49	32	60 : 40	32	27	54 : 46
70-74	488	303	62 : 38	77	47	62 : 38	62	29	68 : 32
75-79	445	379	54 : 46	84	83	50 : 50	76	45	63 : 37
80-84	327	327	50 : 50	78	85	48 : 52	66	54	55 : 45
85-99	244	450	35 : 65	44	87	34 : 66	71	89	44 : 56
Sub-totals	1,860	1,662		332	334		307	244
	Patients = 3,522			Patients = 666			Patients = 551

ISSN: 1471-2458